Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Parallel-Group, Single-Dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants

Trial Profile

A Randomized, Open-Label, Parallel-Group, Single-Dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs Abatacept (Primary)
  • Indications Diffuse scleroderma; Inflammation; Interstitial lung diseases; Juvenile rheumatoid arthritis; Lupus nephritis; Myositis; Nephrotic syndrome; Psoriatic arthritis; Pulmonary sarcoidosis; Rheumatoid arthritis; Sjogren's syndrome
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top